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Structural and thermodynamic 
basis for the recognition of the 
substrate-binding cleft on hen 
egg lysozyme by a single-domain 
antibody
Hiroki Akiba1,2,11, Hiroko tamura3,10,11, Masato Kiyoshi  4, Saeko Yanaka  5,6, Kenji Sugase  5,7, 
Jose M. M. caaveiro 1,8* & Kouhei tsumoto  1,2,3,9*
Single-domain antibodies (VHHs or nanobodies), developed from heavy chain-only antibodies of 
camelids, are gaining attention as next-generation therapeutic agents. Despite their small size, the 
high affinity and specificity displayed by VHHs for antigen molecules rival those of IgGs. How such 
small antibodies achieve that level of performance? Structural studies have revealed that VHHs tend to 
recognize concave surfaces of their antigens with high shape-complementarity. However, the energetic 
contribution of individual residues located at the binding interface has not been addressed in detail, 
obscuring the actual mechanism by which VHHs target the concave surfaces of proteins. Herein, we 
show that a VHH specific for hen egg lysozyme, D3-L11, not only displayed the characteristic binding 
of VHHs to a concave region of the surface of the antigen, but also exhibited a distribution of energetic 
hot-spots like those of IgGs and conventional protein-protein complexes. The highly preorganized 
and energetically compact interface of D3-L11 recognizes the concave epitope with high shape 
complementarity by the classical lock-and-key mechanism. Our results shed light on the fundamental 
basis by which a particular VHH accommodate to the concave surface of an antigens with high affinity in 
a specific manner, enriching the mechanistic landscape of VHHs.
Immunoglobulin molecules of the IgG family are widely employed as therapeutic agents and increasingly pro-
duced in a variety of formats as drug conjugates or bispecific antibodies1. In addition, fragments of antibodies 
and antibody-like scaffolds of small size devoid of the Fc fragment are increasingly considered as promising 
alternatives because of their unique pharmacokinetic profile2. Because of their smaller size, they are amenable to 
straightforward modifications such as in fusion-proteins or in drug-conjugates by protein engineering technolo-
gies. Among them, miniature single-domain antibodies derived from the variable region of the heavy chain-only 
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antibodies of camelids have gained relevance due to their high therapeutic potential and the robust techniques 
employed to generate them3,4. Indeed, these miniature antibodies, termed VHHs, have already entered the phar-
maceutical market. For example, the bivalent VHH dimer known as caplacizumab was approved in 2018 for 
the treatment of thrombosis in Europe5. VHHs are also valuable sensors for a range of applications6,7, in affinity 
chromatography8–10, as tools in cell-biology11,12, or as co-crystallization chaperons13,14.
The usefulness of VHHs relies on their ability to specifically recognize antigens with high affinity despite their 
small size. An important mechanistic feature of VHHs consists in their ability to target clefts on the surface of 
the antigen molecules3,15,16. VHHs comprise only one domain, and for that reason it is less likely that they will 
adopt the type of large and flat surface displayed by the variable fragments (Fvs) of conventional antibodies. 
Instead, because of their small size, VHHs tend to interact with the concave surface of antigen molecules17. The 
long complementarity determining region 3 (CDR3) of VHHs often protrudes from the body of the antibody and 
docks into clefts located on the surface of antigens with high shape complementarity, in a manner that mimics 
some human and bovine antibodies15. It is believed that in this way, VHHs compensate for the limitations of their 
small size, while maintaining the high affinity and specificity that constitute the hallmarks of antibodies17. This 
mechanism has been observed in a structural study that compared the binding mode of VHHs with that of Fvs 
using hen egg lysozyme (HEL) as a model antigen18. Several more studies have revealed additional details of how 
VHHs target the concave surface of antigen molecules19–27. However, the energetic contribution of each individ-
ual residue to the strength of the antibody-antigen complex has not been examined in detail, and therefore the 
mechanism by which VHHs favor concave surfaces of antigens is still incomplete.
Herein, we sought to reveal the molecular and energetic basis for antigen recognition by a VHH to an unprec-
edented level of detail. For that purpose, a VHH termed D3-L11 recognizing the active site of HEL18 was selected. 
The characteristic roles of the residues located at the antigen-antibody interface were examined using site-directed 
mutagenesis with high-resolution calorimetric techniques, NMR, and X-ray crystallography. We explain the fun-
damental basis by which D3-L11 accommodate to an antigen cleft with high affinity in a specific manner.
Results
Energetic basis for the antibody-antigen interaction. The kinetic parameters of the interaction 
between the VHH antibody termed D3-L11 and its antigen HEL were determined by surface plasmon resonance 
(SPR) analysis at 25 °C (Fig. 1a). The values of the association rate constant (kon = 6.1 ± 1.6 × 106 M−1 s−1) and dis-
sociation rate constant (koff = 7.9 ± 1.7 × 10−4 s−1) were determined as described in the methods section, resulting 
in a dissociation constant in the sub-nanomolar range (KD = 0.13 ± 0.04 nM). These values were consistent with 
the data reported in the literature for this antibody18.
Thermodynamic parameters were calculated by the van’t Hoff approximation (constant values within a narrow 
range of temperatures) as described in materials and methods. Binding is driven by a favorable change of enthalpy 
(ΔHvH = −17 ± 1 kcal mol−1) and opposed by the change of entropy (−TΔSvH = 3.1 ± 1.1 kcal mol−1) resulting in 
a large and favorable change of free energy (ΔGvH = −14 ± 2 kcal mol−1) (Supplementary Information Figs S1 and 
S2). The thermodynamic parameters in the transition state were determined by the Eyring approximation using 
the association rate constants (Supplementary Information Fig. S3). The values of change of enthalpy, change of 
entropy and change of free energy at the transition state were 8.4 ± 0.6 kcal mol−1, 0.3 ± 0.7 cal K−1 mol−1, and 
8.0 ± 0.9 kcal mol−1, respectively. The values of all three thermodynamic parameters throughout the reaction 
coordinate are represented schematically in Fig. 1b.
Collectively, the interaction between D3-L11 and HEL is strongly dependent on the enthalpic component sug-
gesting that non-covalent interactions drive the recognition of the antigen by D3-L11. The overwhelming influ-
ence of the change of enthalpy in the formation of the antibody-antigen complex was corroborated by isothermal 
titration calorimetry (ITC), yielding a large value for the change of enthalpy (ΔH° = −21.4 ± 0.6 kcal mol−1) 
(Fig. 1c). The high affinity of the complex between D3-L11 and HEL precluded a more detailed analysis of the 
entropy and free energy by this technique. The difference of ~4 kcal mol−1 between the calorimetric enthalpy and 
the van’t Hoff enthalpy calculated from SPR data (corresponding to a 20% of the total value) is likely related to the 
methodology to calculate it (a direct determination in ITC vs. the van’t Hoff method in SPR) and/or the presence 
of detergent in the buffer employed for SPR. Despite this modest difference, the principle that the binding is 
driven by the change of enthalpy and opposed by the entropy component is consistent in both techniques.
Individual contribution of VHH’s interfacial residues to the binding affinity. To analyze the con-
tribution of the side chains of each residue at the binding interface, first the crystal structure of the D3-L11·HEL 
complex was determined at 1.65 Å resolution (Supplementary Information Table S1). Overall, the crystal struc-
ture was essentially identical to that previously reported (PDB ID: 1ZVY). The root mean square deviation 
(RMSD) value between Cα atoms of VHH and between Cα atoms of HEL in each crystal structure as calculated 
with COOT28 was 0.49 Å and 0.54 Å, respectively (Supplementary Information Fig. S4). It is observed that the 
CDR3 region of D3-L11 protruded into a cleft of HEL, comprising 68% of the buried surface area of the binding 
interface (491 Å2 of a total of 719 Å2) with high complementarity (Sc = 0.78). The list of residues appearing at the 
antibody-antigen interface with a buried surface area greater than 10 Å2 as identified with the PISA server29 are 
listed on the Supplementary Information Table S2.
We prepared single alanine-mutants corresponding to each of these residues (Supplementary Information 
Fig. S5). The structural integrity of each of the mutants was verified by circular dichroism (Supplementary 
Information Fig. S6). The thermal stability of D3-L11 was monitored by differential scanning calorimetry (DSC), 
confirming that all the mutants were stable at physiological temperatures (Supplementary Information Fig. S7). 
The mid-point temperature (TM) at which thermal unfolding of wild-type (WT) or mutant antibodies ocurred was 
determined to be in the range 62–69 °C (Table 1). The heat map in Fig. 2a identifies the locations of the residues 
3Scientific RepoRtS |         (2019) 9:15481  | https://doi.org/10.1038/s41598-019-50722-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
whose Ala mutations were prepared, as a function of their effect in the thermal stability (ΔTM = TM
mutant − TM
WT). 
Positive and negative values indicate a gain or loss of stability, respectively. The CD and calorimetric data thus ver-
ified the integrity of the mutants for the follow-up experiments.
The binding interaction between each mutant and its antigen HEL was evaluated by SPR (Figs 2b and 3, 
Table 2, and Supplementary Information Fig. S8). Among the mutants, only K101A showed higher affinity for 
HEL than the WT antibody (1.4-fold tighter binding corresponding to a favorable ΔΔG° = −0.2 kcal mol−1) 
Figure 1. D3-L11 recognizes HEL with high affinity. (a) Binding of VHH to immobilized HEL at 25 °C 
monitored by SPR. The sensorgrams corresponded to the signal obtained from two-fold dilution series between 
2 nM (darkest blue) and 0.125 nM (lightest blue). The black traces corresponded to the best fit to a 1:1 binding 
model. (b) Energy diagram of the interaction of D3-L11 with HEL with respect to the unbound state. Left, 
center, and right, corresponded to the unbound, transition, and equilibrium states, respectively. Errors bars 
corresponded to the standard error. (c) Titration of D3-L11 with HEL by ITC. The top panel shows the injection 
data (red, baseline). The bottom panel corresponded to the binding isotherm, (red, non-linear fitting). The slope 
of the binding isotherm was too steep for a precise estimation of the dissociation constant. In contrast, this 






WT 66.79 ± 0.01 0 0
E32A 67.26 ± 0.02 0.47 +1
Y52A 68.79 ± 0.01 2.00 +4
H54A 66.78 ± 0.01 −0.01 −1
T55A 63.74 ± 0.01 −3.05 −4
K101A 62.43 ± 0.02 −4.36 −7
Y102A 66.38 ± 0.01 −0.41 −2
P104A 63.54 ± 0.02 −3.25 −5
R106A 68.04 ± 0.01 1.25 +3
F107A 66.24 ± 0.01 −0.55 −3
S113A 67.59 ± 0.01 0.80 +2
D115A 62.92 ± 0.02 −3.87 −6
Table 1. Thermal stability of D3-L11 determined by DSC. aValues ± S.E. of the curve fitting.
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despite being the mutant with the lowest stability overall (ΔTM = −4.4 ± 0.1 °C). Except K101A, all other mutants 
displayed lower (or much lower) affinity for the antigen than WT antibody. From a kinetic point of view, the mea-
ger performance of these mutants was generally linked to a faster dissociation of the antibody-antigen complex 
(greater values of koff).
Based on the mutagenesis analysis, residues Y52, Y102 and P104 were identified as hot-spot residues bearing 
a large influence in binding (>100-fold loss of affinity) and therefore resulting in a large energetic contribu-
tion (ΔΔG > 2.7 kcal mol−1). The effect of mutation in the hot-spot residues was so significant that the sen-
sorgrams displayed a box-shape indicating a very fast dissociation rate. The values of KD were also determined 
from their responses in equilibrium (Supplementary Information Fig. S9). The values obtained were 144 ± 22 nM, 
635 ± 66 nM and 44.8 ± 19.0 nM for Y52A, Y102A and P104A, respectively. These values were uniformly greater 
than those obtained by global analysis by 2-3.5-fold (i.e. weaker affinity than that obtained by global analysis), 
but the order of affinities calculated by either method (Y102A < Y52A < P104A << others) was uniform in both 
calculations.
Thermodynamic dissection of hot-spot tyrosine residues. The thermodynamic basis of the contri-
bution of the two hot-spot tyrosine residues to the binding and to the transition state were next determined by 
the van’t Hoff and Eyring approximations, respectively (Supplementary Information Figs S10–S12). The ther-
modynamic parameters are given in Table 3. The removal of the aromatic side-chain of Tyr52 or Tyr102 resulted 
in large losses of change of free energy with respect to the WT antibody. In Y52A, the change of free energy was 
significantly diminished (ΔGvH = −10 ± 1 kcal mol−1, corresponding to KD = 46 ± 19 nM at 25 °C), whereas in 
Y102A it was even less favorable (ΔGvH = −8.7 ± 4.0 kcal mol−1 corresponding to KD = 413 ± 667 nM at 25 °C). 
The values obtained when calculations were carried out with dissociation constants obtained from the Scatchard 
plots were consistent with the data presented just above within experimental error (Supplementary Information 
Figs S13–15 and Supplementary Information Table S3).
Importantly, the meager affinity between HEL and the mutated antibodies was caused by a significant loss 
in the change of enthalpy with respect to wild type antibody. In Y52A and Y102A the loss of enthalpy with 
respect to WT antibody was 6.0 ± 1.4 kcal mol−1, and 5.0 ± 3.2 kcal mol−1, respectively (Table 3). The loss of 
enthalpy was not compensated by a favorable change of entropy of similar magnitude, leading to weaker bind-
ing. Analogous conclusions were obtained when the analysis was carried out with the parameters from the 
binding at equilibrium (Supplementary Information Table S3). Furthermore, similar observations were made 
when the analysis was carried with the orthogonal technique of ITC (Supplementary Information Figs S16–S17 
and Supplementary Information Table S4). The large loss of enthalpy with respect to WT antibody in Y52A 
(ΔΔH° = 9.1 ± 1.4 kcal mol−1) and Y102A (ΔΔH° = 4.8 ± 3.3 kcal mol−1) is consistent with the conclusion made 
above by SPR, although similarly to WT, the value of enthalpy obtained by ITC in mutant Y52A was slightly 
above the error limits of the value of enthalpy calculated by SPR.
In the transition state, the change of free energy and the change of enthalpy were unfavorable and remarkably 
similar to each other (ΔG‡ = 8.0 ± 0.9 kcal mol−1; ΔH‡ = 8.4 ± 0.6 kcal mol−1) (Table 3). Predictably, the change 
of free energy of the mutants with respect to WT is more unfavorable in the modified antibodies, suggesting 
that loss of affinity in equilibrium is already influenced by the events at the transition state. When the energetic 
terms were dissected it was observed that, contrary to the situation in equilibrium, the change of enthalpy (ΔH‡) 
observed in both Y52A and Y102A was stabilizing (ΔΔH‡ = −4.1 kcal mol−1 and −1.7 kcal mol−1, respectively). 
In other words, the deleterious effects at this stage of the reaction coordinate in the mutants were of entropic 
nature, suggesting more unfavorable rearrangement of VHH and/or water molecules in the mutants than in the 
WT antibody.
Figure 2. Site-directed mutagenesis. The figure shows the distribution of residues mutated to alanine. Mutated 
residues are depicted with sticks. (a) Residues are colored according to the effect of the mutation on ΔTM. Blue 
and red indicate greatest stabilizing and destabilizing effect, respectively. (b) Residues are colored depending on 
the effect of the mutation on the affinity, quantified with respect to WT antibody. Blue indicates a gain of affinity. 
Green to red signals an increasing loss of affinity.
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Figure 3. Binding of mutants. SPR sensorgrams corresponding to the binding of few D3-L11 mutants to HEL 
at 25 °C. Data for additional mutants are found in Supplementary Information Fig. S8. (a) WT (same as Fig. 1a). 
(b) K101A, corresponding to the only mutant in which the affinity increased with respect to WT. (c–f) Mutants 
E32A, R106A, Y52A, and Y102A showing less affinity for HEL. Experimental data is shown in blue (WT) or 
green (mutants). The color darkens as the concentration of VHH gradually increased in the experiment. Other 
details as in Fig. 1a. The concentrations employed were: (a) 2 nM to 0.125 nM (b–d) 16 nM to 0.25 nM, (e) 1024 
to 16 nM, and (f) 2048 to 32 nM, in all cases in two-fold dilutions.
kon (×106 M−1 s−1) koff (×10−3 s−1) KD (nM)
Relative affinity
(KDmut/KDWT)
WTa 6.10 ± 1.62 0.785 ± 0.170 0.129 ± 0.044 1
E32Ab 6.43 ± 0.02 12.0 ± 0.5 1.87 ± 0.01 15
Y52Ab 2.77 ± 0.02 128 ± 9 46.1 ± 0.5 358
H54Ab 3.48 ± 0.01 9.21 ± 0.39 2.65 ± 0.02 21
T55Ab 3.77 ± 0.04 11.3 ± 1.1 2.99 ± 0.04 23
K101Ab 7.54 ± 0.01 0.687 ± 0.008 0.0911 ± 0.0002 0.7
Y102Ab 2.32 ± 0.02 686 ± 75 295 ± 4 2,299
P104Ab 17.4 ± 0.6 226 ± 77 13.0 ± 0.6 101
R106Ab 1.11 ± 0.00 1.83 ± 0.05 1.65 ± 0.01 13
F107Ab 8.99 ± 0.08 14.7 ± 1.4 1.63 ± 0.02 13
S113Ab 5.17 ± 0.11 8.31 ± 1.6 1.61 ± 0.04 13
D115Ab 6.11 ± 0.01 0.956 ± 0.013 0.156 ± 0.000 1.2
Table 2. Kinetic and thermodynamic parameters obtained from SPR. aValues ± S.D. from seven independent 
experiments. bValues ± S.E of the fitting to the sensorgrams.
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Structural analysis. The large loss of affinity of Y102A (~2,300-fold) with respect to WT prompted a more 
detailed structural analysis by X-ray crystallography. The complex Y102A·HEL was determined at 1.50 Å and 
1.55 Å resolution, respectively. The complex of the mutant with the antigen superimposed onto the complex 
with WT antibody is shown in Fig. 4a. A close-up view of the mutated residue and its environment is depicted in 
Fig. 4b. Except for the presence of a molecule of cryoprotectant (glycerol) filling up the vacancy of the side-chain 
of Tyr102, no other significant differences with respect to WT antibody were observed, such as in the conforma-
tion of the neighboring residues of Ala102, or in residues contributing to the affinity (Glu32, Tyr52, His54, Thr55, 
Pro104, Arg106 and Phe107). Similarly, the shape complementarity remained high as shown by the little change 
in the Sc parameter (Sc = 0.76). Although the mutation Y102A considerably impaired the binding affinity for the 
antigen, the conformation of the antibody-antigen interface remained largely unaffected.
The X-ray structure of WT D3-L11 in the absence of the antigen was also determined, achieving a resolution 
of 1.15 Å. The coordinates of unbound D3-L11 were aligned to those of the antibody in complex with HEL using 
the Cα atoms of the residues of the framework region (FR) (Fig. 5). The conformation of the residues contribut-
ing to the affinity did not change significantly in the unbound form compared to the antibody-antigen complex 
(RMSD = 0.76 Å among main chain α-carbons). Collectively, the X-ray data suggests that the interface residues 
of VHH contributing to binding the antigen adopted a rigid conformation.
To clarify the conformational fluctuation of these residues, the R2 dispersion parameters were determined 
by NMR. This method is employed to characterize fluctuations in the microsecond to millisecond scale, which 
is within the relevant time scale for protein function. Only six residues displayed values of Rex greater than 1 s−1 
(Lys74, Asn77, Met78, Tyr80, Cys96 and Val103) (Fig. 6). Those residues with significant fluctuations (Rex > 5 s−1) 
were exclusively located in the FR3 (Lys74, Met78, Tyr80). Except for Val103, residues in the CDRs showed little 
fluctuation, suggesting that the CDRs were little dynamic in solution, in agreement with the conclusions extracted 
from the crystallographic data.
Discussion
The combination of thermodynamic, structural and dynamic information is a powerful tool to accurately describe 
interaction phenomena like that in the recognition of antigens by antibodies. Herein we report that the recogni-
tion mode of D3-L11 for its antigen HEL shared some features in common with Fv from conventional antibodies30  
and some features in common with other VHHs31,32. The present study further dissected the roles of each residue 
at the binding interface by alanine-scan mutagenesis.
ΔGvH ΔΔGvHb ΔHvH ΔΔHvHb −TΔSvH −TΔΔSvHb ΔCp,vH ΔG‡ ΔH‡ −TΔS‡
kcal mol−1 kcal mol−1 kcal mol−1 kcal mol−1 kcal mol−1 kcal mol−1 kcal K−1 mol−1 kcal mol−1 kcal mol−1 kcal mol−1
WT −14 ± 2 — −17 ± 1 3.1 ± 1.1 — −0.024 ± 0.186 8.0 ± 0.9 8.4 ± 0.6 −0.32 ± 0.66
Y52A −10 ± 1 4.0 ± 2.2 −11 ± 1 6.0 ± 1.4 0.68 ± 0.54 −2.4 ± 1.2 −0.16 ± 0.07 8.8 ± 0.2 4.3 ± 0.1 −4.5 ± 0.1
Y102A −8.7 ± 4.0 5.3 ± 4.5 −12 ± 3 5.0 ± 3.2 3.2 ± 2.9 0.1 ± 3.1 0.15 ± 0.48 8.8 ± 1.3 6.7 ± 0.9 −2.1 ± 0.9
Table 3. Thermodynamic binding parameters (SPR)a. aValues ± S.E of the curve fitting based on van’t Hoff or 
Eyring plots. bΔΔGvH = ΔGvH,mutant − ΔGvH,WT, ΔΔHvH = ΔHvH, mutant − ΔHvH, WT; −TΔΔSvH = (−TΔSvH, 
mutant) − (−TΔSvH,WT).
Figure 4. Crystal structure of the antibody-antigen complex. (a) Superimposed structures of the complex 
WT·HEL with that of the mutant Y102A·HEL. Alignment was carried out on the antigen. WT, Y102A, and HEL 
are shown in orange, green and gray, respectively. The side chains of residues influencing binding (loss of affinity 
>10-fold) are depicted with sticks. (b) Close-up view of the environment around Tyr102. The position of the 
side chains of the residues contributing to the affinity of the complex were not altered by the mutation. The 
vacancy generated by the removal of the side chain at position 102 was filled by a molecule of cryoprotectant 
(glycerol).
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Previous studies have suggested a dominant role for the CDR3 in the recognition of antigens by antibodies 
of the VHH class17. The CDR3 region stems from recombination of all of V, D and J gene segments, and somatic 
hypermutation, becoming the most diverse CDR in length and sequence in antibodies33. The analysis of D3-L11 
carried herein supports this general idea, and embraces the concept of three-dimensional proximity around a core 
Figure 5. Crystal structure of unbound VHH. (a) Comparison of unbound D3-L11 (blue) with that in complex 
with HEL (green). HEL is shown in light purple. Overlaid structures using the three CDR loops. Backbone 
with the side chains of residues showing influence in binding (affinity loss >10-fold). (b) Enlarged view of 
the VHH binding interface from panel (a). The unbound and bound antibodies are depicted in cyan and gray, 
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Figure 6. Fluctuation of residues of D3-L11 (main chain). (a) Structure of D3-L11 displaying the residues 
with the greatest fluctuations (sticks in magenta gradient). The key recognition regions CDR1, CDR2, and 
CDR3 are colored in cyan, green, and yellow, respectively. Other regions are shown in gray. (b) R2 dispersion 
profiles of Lys74 and Cys96 collected at 14.1 T (black) and 17.6 T (red) are shown. The residues were selected as 
representative examples of a residue displaying a large fluctuation, and that of a residue with no fluctuation.
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of key residues acting as energetic hot-spots. Of the three hot-spots residues identified in D3-L11, two of them are 
located in the CDR3 and one in the CDR2. These three residues are clustered together in the three-dimensional 
structure, and uniformly surrounded by a constellation of residues of lesser but still appreciable importance for 
binding the antigen. This uniform layer comprises residues belonging to each of the three CDR regions of the 
VHH.
This kind of arrangement is commonly observed in the paratope of Fvs and in the interaction surface of 
protein-protein complexes30,34–36. However, an important difference between Fvs and D3-L11 is observed. 
Whereas Fvs generally recognize planar epitopes37–39, D3-L11 recognize a cleft on the surface of the antigen with 
high shape complementarity (Sc > 0.75), a signature characteristic of numerous other VHHs18. The results pre-
sented herein demonstrated that hot-spot residues coalescing on a small geometric region are characteristic not 
only when interacting with the planar surface of antigens such as in Fvs, but can also occur in a VHH recognizing 
a concave surface of the antigen.
In contrast, this arrangement of residues is not common among other VHHs. Generally, VHHs of known 
structure display long, extended CDR3 (or less commonly, CDR1)40 that interact with the antigen epitope inde-
pendently from other regions of the VHH moiety21,23–25. For example, a previous study of a VHH exhibiting a 
protruding CDR3 indicated that the most determining residues were present in the extended CDR3, but not 
outside of it21. The constellation of residues of VHH in that study is clearly different from that of D3-L11, even if 
there are also some similarities in other parts of the CDR3. In the majority of VHHs with long CDR3, and D3-L11 
is not an exception, this loop covers a relatively hydrophobic surface of the framework region 2 (FR2) of the VHH 
molecule. These miniature antibodies utilize the long CDR3 loop to naturally act as a part of the single domain 
antibody, rather than as an independent element. The equivalent surface in Fv is located between the VL and VH 
regions41.
The structural data showed only minor differences in the conformation of the main chain between unbound 
and bound D3-L11, suggesting that preorganization of the interaction surface is a key aspect of the mechanism 
of recognition. The rigidity of the residues comprising the interaction surface would ensure a highly cooperative 
mode of interaction of the three CDR loops, enhancing the affinity for the antigen. Similar structural character-
istics were observed for a VHH interacting with a shallow concave surface of its antigen26. In contrast, in VHHs 
where CDR3 protrudes to access deep concave sites the structural data revealed large differences between the 
complexed and unbound structures21,27. Mixed of VHHs binding concave sites of antigens without protruding 
CDRs show slight reorganization of the residues of these CDRs loops upon binding20,22,27. In our case, because 
both HEL42 and D3-L11 (this study) are rigid, the interaction could be explained with classical mechanism of 
lock-and-key43. The results of thermodynamic analysis including dominant enthalpic component throughout the 
association process and reduced enthalpy upon hot-spot mutagenesis are consistent with this model. Despite the 
little structural change of the interface residues, binding is strongly opposed by the change of entropy suggesting 
an intricate role for the solvent.
In conclusion, the paratope of the VHH antibody D3-L11 recognized its epitope by a lock-and-key mecha-
nism, and is organized similarly to that of a conventional antibody (Fvs). Although this mechanism is not com-
mon among VHHs, the high affinity of D3-L11 indicates that mimicking Fvs may also work for a VHH to achieve 
its high affinity and specificity, the two hallmarks of antibodies. Because the long CDR3 covers the surface that 
emerges in the absence of the VL domain of IgGs, diversity in this loop is fully employed to generate a preor-
ganized interface on the convex surface of the VHH. This organization is suitable to recognize concave sur-
face of antigens, complementing the more common mechanism of protrusion of CDR observed in other VHHs. 
Diversity in binding modes enable VHHs to accommodate to various antigen molecules and thus brings VHHs 
advantages over other cleft binders, achieving high affinity and specificity.
Materials and Methods
Cloning, expression and purification of D3-L11. A synthetic gene of D3-L11 optimized for Escherichia coli 
(Genscript) was cloned in pRA244 between NcoI and SacII restriction sites. The construct also contained a pelB 
signal peptide at the N-terminus, and a His6-tag at the C-terminus. For expression, E. coli strain BL21(DE3) car-
rying the expression vector of D3-L11 were grown in 1 L of LB medium containing 50 μg/mL ampicillin at 28 °C 
and 120 rpm. Expression was induced by addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside when the 
optical density at 600 nm reached 0.5 after which the temperature was reduced to 20 °C overnight. The cells were 
harvested by centrifugation (7,000 × g for 15 min) at 4 °C. The cell pellet was resuspended in buffer A (20 mM 
TRIS-HCl, 500 mM NaCl, pH 8.0) supplemented with 5 mM imidazole, after which it was lysed with an ultrasonic 
disruptor (UD-201, TOMY) for 15 min. The cell lysate was centrifuged (40,000 × g for 30 min) at 4 °C. The super-
natant was filtered through a membrane of a nominal pore size of 0.45 μm and subsequently loaded onto a 1 mL 
of Ni-NTA agarose column (Qiagen) equilibrated with buffer A. After a washing step with Buffer A containing 
100 mM imidazole, VHHs were eluted from the column with buffer A supplemented with 500 mM imidazole. 
The eluate was dialyzed against buffer A, and subjected to size-exclusion chromatography (SEC) using a HiLoad 
26/600 superdex 75 pg column (GE Healthcare) equilibrated with a buffer containing 20 mM TRIS-HCl, 150 mM 
NaCl, and 1 mM EDTA at pH 7.4.
For crystallization of the unbound form of D3-L11, the gene encoding the antibody was cloned into a 
Champion pET-SUMO vector bearing a His6-SUMO-tag. The protein was expressed as above. After the affin-
ity chromatography step, the His6-SUMO-tag was cleaved-off with Ulp1 protease overnight at 4 °C in 20 mM 
TRIS-HCl, 150 mM NaCl at pH 8.0. The protein was separated from the protease, from the cleaved tag, and from 
the uncleaved protein by immobilized metal-affinity chromatography. The flow-thorough was concentrated and 
subjected to SEC using a HiLoad 16/600 superdex 75 pg column as described above.
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Preparation of the antigen. HEL was purchased from Wako Pure Chemical (Cat. No. 126-02671, Japan) 
and solubilized in phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4) at the desired concentration and used without further purification.
Circular dichroism. The secondary structure of D3-L11 was examined in a CD J-820 spectrometer (Jasco, Japan) 
with a 1-mm quartz cuvette. Measurements were performed in a buffer containing 20 mM TRIS-HCl, 150 mM 
NaCl, 1 mM EDTA, pH 7.4 at a protein concentration of 10 μM. The spectrum of each sample was recorded five 
times at a speed of 50 nm/min and at 25 °C.
Differential scanning calorimetry. Thermal stability of D3-L11 and mutants (20 μM) was monitored with 
a VP-Capillary DSC instrument (MicroCal) in PBS. Samples were scanned at a speed of 1 °C/min from 10 to 
100 °C. Data analysis was performed with Origin 7.0 using a non-two-state denaturation model.
Surface plasmon resonance. The binding of D3-L11 to HEL was determined by SPR using a Biacore 
T200 instrument (GE Healthcare). HEL (6.5 μg/mL) in 10 mM sodium acetate at pH 5.5 was immobilized onto 
a Series S CM5 Sensor Chip at 200 RU as previously described45,46. Measurements were performed at 25 °C in 
PBS buffer supplemented with the detergent Tween 20 (0.005%). Contact and dissociation times were 300 and 
600 sec, respectively. The range of concentrations of D3-L11 was adjusted depending on the mutation studied and 
indicated where appropriate. Regeneration was conducted with 1.0 M Arg-HCl at pH 4.4 for 60 sec. To obtain 
the thermodynamic parameters the experiments were conducted at several temperatures. Data analysis was con-
ducted with the instrument’s BiaEvaluation Software. Global fitting analysis and Scatchard plots were performed 
with a 1:1 binding model. The thermodynamic parameters were determined with the BiaEvaluation Software 
employing non-linear regressions (van’t Hoff plot) or linear regressions (Eyring plots). The van’t Hoff analysis of 
WT was not conducted with the data obtained from the Scatchard plot because the association step did not reach 
a plateau under the experimental conditions tested. In the experiments with the mutants at 30 °C, non-specific 
binding significantly affected the sensorgrams, and thus these data were excluded from the analysis.
Isothermal titration calorimetry. ITC measurements were carried out in an iTC200 instrument 
(Microcal) at 25 °C and a stirring rate of 1000 rpm in PBS buffer. The WT antibody or its mutants (10 μM) were 
titrated with HEL (100 μM) by injecting one-time 0.5 μL followed by 18 injections of 2.0 μL each with a fixed time 
between injections of 120 sec. The binding isotherm was fitted by non-linear regression with the program Origin 
7.0 to a 1:1 binding model to obtain the thermodynamic parameters of the interaction.
Crystallization. For the crystallization of the antibody·antigen complexes, WT or Y102A antibody was mixed with 
ca. 5-fold excess of HEL in PBS, followed by dialysis against a buffer containing 20 mM TRIS-HCl, 100 mM NaCl, pH 
8.0 overnight. The antibody-antigen complex was separated from excess HEL by SEC using a HiLoad 16/600 superdex 
75 pg column equilibrated in the same buffer. The protein sample was concentrated to 13 mg/mL (WT-HEL complex) 
or 8.3 mg/mL (Y102A-HEL complex) in an Amicon Ultra-4 unit (molecular weight cutoff 10 kDa). Preliminary crys-
tallization experiments were explored by mixing an equal volume of precipitant solution and protein solution in an 
Oryx8 instrument (Douglas Instruments) using commercial sparse matrix screens (Hampton Research) at 20 °C. Each 
complex (WT·HEL or Y102A·HEL) was crystallized in a solution containing 100 mM sodium nitrate and 16% PEG-
3350 (pH 8.0). The complex between HEL and the mutant Y102A was independently crystalized in a buffer containing 
100 mM lithium chloride and 18% PEG-3350. Crystals of WT D3-L11 (10 mg/mL) in the unbound form were obtained 
in a solution containing 100 mM Tris-HCl and 2.15 M ammonium sulfate at pH 7.0.
Data collection and refinement. Data were collected in beamlines BL5A and AR-NW12 at the Photon 
Factory (Tsukuba, Japan) under cryogenic conditions (100 K). The diffraction images were processed with the 
program MOSFLM and subsequently merged and scaled with the program SCALA of the CCP4 suite47. The struc-
tures were determined using the method of molecular replacement with the program PHASER48. The coordinates 
were refined with the program REFMAC549, and manually improved with COOT28. Validation was carried out 
with PROCHECK50. No residues were found in the disallowed regions of the Ramachandran plot. Residues were 
numbered sequentially. Kabat sequence numbering is shown in Supplementary Information Table S5. Data col-
lection and refinement statistics are given in Supplementary Information Table S1.
R2 dispersion (NMR). Three-dimensional spectra of HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB, 
and HN(CO)CACB were measured on an AVANCE DRX600 spectrometer (Bruker BioSpin) for sequential 
assignments of the backbone 1H, 13C, and 15N chemical shifts51 of free D3-L11 using the protein dissolved at 
0.5 mM in NMR buffer (95% H2O/5% D2O, 20 mM sodium phosphate [pH 7.4], 143 mM NaCl). NMR data 
were processed and analyzed as previously described52. 15N effective R2 relaxation rates were measured at 37 °C 
on AVANCE DRX600 and AVANCE DMX750 spectrometers (Bruker BioSpin) using the 1H continuous-wave 
Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence53. Effective R2 rates were calculated as described previ-
ously54. Relaxation dispersion data whose R2 values changed by <1 s−1 over the entire range of τcp were excluded. 
By using the program GLOVE55, the relaxation dispersion curves were fitted to a two-state exchange model.
Accession numbers. The coordinates and structure factors of unbound D3-L11 (entry code 6JB9), WT 
D3-L11 in complex with HEL (entry code 6JB8), and Y102A D3-L11 in complex with HEL (entry codes 6JB2 and 
6JB5) have been deposited in the Protein Data Bank.
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